12:00 AM
Jul 16, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/13 cls
Acorda (ACOR) Lazard Joel Sendek Price target Buy 6% $20.70
Sendek raised his target to $32 from $30. He said a survey of neurologists suggests that the potential market for ACOR's Fampridine-SR is larger than he previously modeled. The sustained-release formulation of 4-aminopyridine (4-AP) is in Phase III testing for multiple sclerosis (MS).
Alnylam (ALNY) Banc of America Securities William Ho Other Buy 53% $23.24
Piper Jaffray Edward Tenthoff Price target Market outperform
Rodman Michael King Price target Market outperform
Ho maintained his $30 target after ALNY granted Roche (SWX:ROG) a non-exclusive license to its RNAi technology, a research facility and a 5% stake for $331M up front, including an equity investment. He said the deal continues to validate the RNAi platform and that it should become a benchmark for future collaborations (see "RNAi(ndependence)," A8).
Tenthoff raised his target to $30 from $23 on the deal.
King raised his target to $30 from $25. He said the agreement gives ALNY a solid cash...

Read the full 1073 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >